Scholars Central

CommentaryPublished 2015

API Supplier Change or Addition of Alterate API Supplier in Generic Drug Products: Cost, Quality and Regulatory Factors

Authors: Useni Reddy Mallu, Arunkanth Krishnakumar Nair, Hanimi Reddy Bapatu, Pavan Kumar M, Santosh Narla, Jonna Sankar, Tejas, Narendra Kumar Thamma, NVVSS Raman

Pharmaceutica Analytica Acta

Volume 6 · Issue 5 · Pages 1–8

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Generic drug product (GDP) competition for market existence and profitability has become a challenging task for the manufacturers. All the generic players are putting intensive efforts to enter the market with competitive price and consistent drug product (DP) quality. The generic firms have to manage the delicate balance between the cost and quality of raw materials, especially the active pharmaceutical Ingredient (API) for market survival. Major Pharma companies have adopted the merger and acquisition strategies with API manufacturers to withstand the competition and price erosion. Still the majority firms don’t have their own API manufacturing facility. Since the finished product cost is majorily driven by API, the supplier selection plays prominent role in the generic profitability as well as quality. The supplier screening and selection includes extensive evaluation and comparison of documents, quality and cost. As part of risk mitigation strategy many generic manufactures prefer to include additional or alternate sources for API supplier. This exercise could be triggered anytime during the DP life cycle. The authors have tried to share the view on supplier change process at various stages of product lifecycle and related regulatory authority requirements and expectations. Generic products have been targeted majorly for US and Europe regions and same is being focused here. These two regulatory bodies have almost similar requirement for supplier selection and change, except difference in procedural approaches. The regulatory requirements may vary for each phase of generic product life cycle. At the development stage, the supplier change may not significantly fall into regulatory umbrella. Generally development phase comes under relatively less regulatory scruitiny than CTD submission or post approval phase. The dossier review and post approval phase have almost similar regulatory requirements. All the post approval changes shall be routed through SUPAC filing in US and VARIATION filing procedures in Europe.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Pharmaceutica Analytica Acta.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPharmaceutica Analytica Acta
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Useni Reddy Mallu”
  • BylineArticles whose byline prints “Arunkanth Krishnakumar Nair”
  • BylineArticles whose byline prints “Hanimi Reddy Bapatu”
  • BylineArticles whose byline prints “Pavan Kumar M”
  • BylineArticles whose byline prints “Santosh Narla”
  • BylineArticles whose byline prints “Jonna Sankar”
  • BylineArticles whose byline prints “Tejas”
  • BylineArticles whose byline prints “Narendra Kumar Thamma”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels